52 Week Range
As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Bausch Health Companies Inc Announces Fourth-Quarter And Full-Year 2020 Results, Provides 2021 Guidance
Glenview Capital Management Releases Letter To Joe Papa, CEO
BAUSCH HEALTH RESPONDS TO SCHEDULE 13D FILING FROM ICAHN CAPITAL LP
Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.
Biotechnology & Drugs
2150 Saint-Elzear Blvd W
Joseph C. Papa
Chairman of the Board, Chief Executive Officer
Paul S. Herendeen
Chief Financial Officer, Executive Vice President
Thomas J. Appio
President & Co-Head Bausch + Lomb/International
Joseph F. Gordon
President & Co-Head Bausch + Lomb/International
Christina M. Ackermann
Executive Vice President, General Counsel
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Bausch Health Companies Inc on Wednesday agreed to add two directors from Icahn Group to its board, weeks after activist investor Carl Icahn disclosed a nearly 8% stake in the Canadian drugmaker.
Bausch Health Companies Inc said on Wednesday it would add two directors from Carl Icahn and affiliated entities to its board, weeks after the billionaire investor disclosed a stake in the company. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
Glenview Capital Management, a shareholder in Bausch Health Companies Inc, sent a letter to the drugmaker's chief executive on Friday, saying the spinoff of the Canadian company's eye care unit should be completed by the end of 2021.
Glenview Capital Management, a shareholder in Bausch Health Companies Inc, said on Friday the Canadian drugmaker should spin off its eye care unit, Bausch Global Eyecare, in an "optimal fashion" in 2021.
Canadian drugmaker Bausch Health Companies Inc said on Thursday it would spin off its eye care unit, Bausch + Lomb, into a separate publicly listed company, seven years after acquiring it for nearly $9 billion.
Canada's main stock index scaled a five-month high on Thursday as a surge in shares of drugmaker Bausch Health and higher oil prices outweighed disappointment over earnings, including Bombardier's surprise quarterly loss.
Canadian drugmaker Bausch Health Companies Inc said on Thursday it would spin-off its eye care unit Bausch + Lomb into a separate publicly listed company.
Bausch Health Companies Inc <BHC.TO> has agreed to pay $45 million, and three of former top executives also agreed to penalties, to settle charges of improper revenue recognition and misleading disclosures in U.S. regulatory filings, the U.S. Securities and Exchange Commission...
Canada-based Bausch Health Companies Inc has agreed to pay a $45 million penalty to settle charges of improper revenue recognition and misleading disclosures in Securities and Exchange Commission filings and earnings presentations, the SEC said on Friday.
* HEALTH CANADA ISSUES NOTICE OF COMPLIANCE FOR BAUSCH HEALTH'S DUOBRII™
Chanel, Revlon and L'Oreal, three of the biggest brands in cosmetics, are quietly moving away from using talc in some products as U.S. cancer lawsuits and consumer concerns mount.
* FDA PROVIDES 510(K) CLEARANCE FOR BAUSCH + LOMB INFUSE™ DAILY DISPOSABLE SILICONE HYDROGEL (SIHY DAILY) CONTACT LENSES
A federal special master said Wednesday that he would grant final approval to a $1.21 billion settlement by Bausch Health Cos Inc of a shareholder class action alleging the company misled investors about its business operations and financial performance when it was called...
A judge on Monday tossed a whistleblower lawsuit alleging Bausch Health Companies Inc fraudulently obtained a patent on its ulcerative colitis drug Apriso, causing artificially high prices to be charged to Medicare and Medicaid.
* BAUSCH HEALTH ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR NOTES AND CONDITIONAL REDEMPTION OF EXISTING SENIOR SECURED NOTES
* BAUSCH HEALTH AND ALFASIGMA ANNOUNCE RESOLUTION OF XIFAXAN® INTELLECTUAL PROPERTY LITIGATION
* FDA APPROVES ORTHO DERMATOLOGICS' LABELING FOR JUBLIA® (EFINACONAZOLE) TOPICAL SOLUTION, 10%, IN PATIENTS AS YOUNG AS SIX YEARS OLD
* CLEARSIDE BIOMEDICAL REVISES NDA RESUBMISSION TIMELINE AND XIPERE™ COMMERCIAL PARTNERSHIP WITH BAUSCH HEALTH
* BAUSCH HEALTH INITIATES VIRAZOLE (RIBAVIRIN FOR INHALATION SOLUTION, USP) CLINICAL STUDY IN PATIENTS WITH COVID-19
* GLENVIEW CAPITAL MANAGEMENT LLC REPORTS 5.10% PASSIVE STAKE IN BAUSCH HEALTH COMPANIES INC AS OF APRIL 8 - SEC FILING Source text : (https://bit.ly/3b80eyg) Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.